A Multicenter, Open-Label Phase II Study of SyB L-0501 in Patients With Relapsed/Refractory Multiple Myeloma

Trial Profile

A Multicenter, Open-Label Phase II Study of SyB L-0501 in Patients With Relapsed/Refractory Multiple Myeloma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2015

At a glance

  • Drugs Bendamustine (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors SymBio Pharmaceuticals
  • Most Recent Events

    • 12 Nov 2013 Status changed from recruiting to discontinued, according to a SymBio Pharmaceuticals media release.
    • 16 May 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 26 Dec 2011 The first patient has been enrolled, according to a SymBio Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top